DOCS: Healthcare Moat And AI Tools Will Support Future Engagement

The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite.

Analyst Commentary

Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth. Price target changes have been frequent, with several reductions partially offset by a few upward or supportive moves.

Bullish Takeaways

Bullish analysts highlight Doximity as more than a simple professional network, pointing to a sticky platform with meaningful network effects that can support user engagement and client retention over time.
Some see what they view as above average growth potential and operating leverage as the business scales, which they argue can support a case for higher long term earnings power relative to the current share price.
The AI tool suite, including DoxGPT, is viewed positively by bullish analysts, who point to its integration within the existing ecosystem, perceived accuracy of clinical responses and supporting evidence base as potential drivers of product adoption.
At least one bullish firm has initiated coverage with a Buy rating and a US$31 price target, and another has raised its target to US$42. These moves indicate that some analysts see room for upside if execution on growth initiatives and AI monetization goes as planned.

Bearish Takeaways

Bearish analysts have downgraded the stock and cut price targets, citing weaker visibility into revenue growth, which raises questions about how predictable and durable the current growth profile will be.
Multiple firms have reduced their price targets by amounts ranging from US$8 to US$30. This pattern suggests a reset of expectations around future revenue trajectories and the timing of potential reacceleration.
Some large banks, including JPMorgan, have maintained more cautious stances such as Neutral ratings while lowering targets. This indicates that they want clearer evidence on execution and growth before taking a more constructive view.
Bearish analysts appear to be weighing the positive story around AI tools and platform scale against concerns that softer revenue visibility could limit valuation expansion if growth does not track prior assumptions.

What's in the News

Doximity completed a share repurchase of 8,648,145 shares, representing 4.6% of shares, for a total of US$417.04 million under the buyback first announced on May 16, 2024 (Key Developments).
Within that program, from October 1, 2025 to December 31, 2025, the company repurchased 4,151,678 shares, or 2.21% of shares, for US$196.84 million (Key Developments).
The Board of Directors authorized a new share buyback plan on February 5, 2026 (Key Developments).
Doximity announced a new share repurchase program for up to US$500 million of its Class A common stock, with no stated expiration date (Key Developments).
For the fiscal fourth quarter ending March 31, 2026, the company issued revenue guidance of US$143 million to US$144 million, and for the fiscal year ending March 31, 2026, revenue guidance of US$642.5 million to US$643.5 million (Key Developments).

Valuation Changes

Fair value was reduced from $39.55 to $37.77, representing a modest cut of about 4.5% in the updated assessment.
The discount rate was adjusted slightly higher from 8.24% to 8.25%, a very small change that still results in a lower present value for future cash flows.
Revenue growth was revised from 8.32% to 7.04%, reflecting a more conservative view of top line expansion in the model.
The profit margin was nudged up from 31.50% to 31.89%, suggesting a slightly stronger long term profitability assumption.
The future P/E multiple eased from 34.37x to 33.61x, indicating a small reset in the valuation multiple applied to forward earnings.

4 views

Key Takeaways

AI-powered workflow tools and high platform engagement drive deeper customer retention, higher revenue per user, and expanding long-term margins.
Broad client demand and digital marketing trends position Doximity for sustained growth, improved sales efficiency, and earnings stability through diversified revenue streams.
Heavy short-term investment in free AI features, dependence on pharma marketing, regulatory risks, and slowing user growth could constrain revenue, margin, and earnings expansion.

Catalysts

About Doximity

Operates as a digital platform for medical professionals in the United States.What are the underlying business or industry changes driving this perspective?

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time-supporting long-term revenue and margin expansion.
Strong, broad-based demand from pharmaceutical, SMB, and health system clients-fueled by a digital-first shift in pharma marketing strategies and expansion of self-service/commercial portals-positions Doximity for sustained top-line growth, particularly as digital advertising continues supplanting traditional outreach, bolstering both revenue growth and sales efficiency.
The stickiness and daily-use nature of Doximity's telehealth, scheduling, and workflow tools-amplified by ongoing healthcare workforce shortages-reinforce Doximity's value proposition and increase switching costs, supporting resilient net revenue retention (>118%) and reducing future churn, which underpins stable earnings and improving EBITDA margins.
Growing penetration and upsell to enterprise health systems (including 17 of the top 20 U.S. systems) and accelerated momentum in recruitment/curative products leverages the regulatory and industry push toward digital, efficient, value-based care solutions, expanding addressable market and diversifying revenue streams, contributing to greater earnings visibility and lower cyclicality.
Internal and product-facing AI initiatives are driving meaningful productivity gains and operational leverage (headcount flat while revenue grows, AI-enabled client portal efficiency), which is likely to support further EBITDA margin expansion and robust free cash flow, even as the company invests heavily in new growth vectors.

Doximity Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Doximity's revenue will grow by 7.0% annually over the next 3 years.
Analysts assume that profit margins will shrink from 37.5% today to 31.9% in 3 years time.
Analysts expect earnings to reach $249.4 million (and earnings per share of $1.33) by about April 2029, up from $239.4 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 33.7x on those 2029 earnings, up from 18.8x today. This future PE is greater than the current PE for the US Healthcare Services industry at 32.2x.
Analysts expect the number of shares outstanding to decline by 1.66% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.25%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

While Doximity is successfully launching AI products like Scribe and integrating new acquisitions, management's decision to offer key advanced features (e.g., Scribe, Pathway corpus, DocsGPT) for free in the near-term could limit direct revenue growth and slow the monetization of its third act; this may delay the positive financial impact typically expected from new product launches, constraining revenue and earnings expansion in the medium term.
Doximity's continued heavy reliance on pharmaceutical marketing spend as its primary revenue driver exposes it to risks from regulatory or policy changes such as potential direct-to-consumer (DTC) bans, industry consolidation, or reduced pharma budgets, which could materially impact top-line growth and profitability over the long run.
The company is experiencing strong broad-based client and user engagement growth, but mentions of "policy uncertainty" and the need for "measured guidance" in the second half of the year highlight ongoing vulnerability to regulatory and healthcare budget fluctuations, introducing uncertainty into renewal rates, revenue predictability, and net margins.
While user engagement metrics are hitting record highs, a significant portion of physician adoption may plateau in the coming years as the platform nears saturation among U.S. clinicians; this dynamic can limit future network effect-driven growth, constricting both revenue momentum and margin leverage opportunities over the longer term.
Although management expects AI investments to drive long-term efficiency, current and upcoming stock-based compensation ("high teens" as a percentage of revenue through 2027) and ongoing OpEx increases for AI personnel and infrastructure may pressure net margins, dilute EPS, and offset some near-term gains from operational scale, particularly if new monetization from AI features lags expectations.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $37.77 for Doximity based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $55.0, and the most bearish reporting a price target of just $25.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $782.1 million, earnings will come to $249.4 million, and it would be trading on a PE ratio of 33.7x, assuming you use a discount rate of 8.2%.
Given the current share price of $24.39, the analyst price target of $37.77 is 35.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Doximity?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks